Peptides Studied for Sexual Health & Fertility
Sexual health and fertility is an area where peptide research has produced one genuine FDA approval and several promising clinical programs. PT-141 (bremelanotide/Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women — the first centrally-acting treatment for female sexual dysfunction.
Kisspeptin, the master regulator of reproductive biology, is being studied as a safer alternative to hCG for IVF triggers and as a treatment for hypothalamic amenorrhea. Oxytocin — one of the most studied peptides in history — has decades of FDA-approved use in obstetrics and growing (though mixed) research for social cognition and mood.
These peptides act through fundamentally different mechanisms: PT-141 through melanocortin receptors in the brain, kisspeptin through the HPG axis, and oxytocin through its own receptor system. Understanding these differences matters for anyone exploring peptide options for sexual health or fertility.
PT-141
Bremelanotide (Vyleesi)
An FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women. Works through the brain to increase desire — a fundamentally different mechanism than PDE5 inhibitors.
Kisspeptin
KISS1 Neuropeptide (Kisspeptin-54/10)
The master regulator of reproductive biology. Being studied for IVF trigger (safer than hCG for OHSS prevention), hypothalamic amenorrhea, and fertility. Multiple Phase 2 trials with strong translational potential.
Oxytocin
Neuropeptide Hormone (Pitocin)
An FDA-approved peptide hormone with decades of obstetric use. Extensively studied for social cognition and mental health — but results are more complex than the 'love hormone' narrative suggests. On the WHO Essential Medicines List.